Cabazitaxel

Independent reference data for Cabazitaxel (CAS 183133-96-2), compiled from public chemistry databases.

Registry identifiers across databases

Computed descriptors

Physicochemical values on record

Documented uses on record

Cabazitaxel is indicated, in combination with [prednisone], for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a [docetaxel]-containing treatment regimen. In Europe and Canada, it can also be used in combination with [prednisolone].Cabazitaxel is a taxane and antineoplastic agent which is currently used in the therapy of castration-resistant metastatic prostate cancer after failure of docetaxel. Therapy with cabazitaxel has been associated with a low rate of serum enzyme elevations, but has not been linked to cases of clinically apparent acute liver injury, although it can cause severe hypersensitivity infusion reactions which in some instances can be associated with acute liver injury.

Synonyms and trade names

CABAZITAXEL; 183133-96-2; Jevtana; Taxoid XRP6258; Xrp6258; Cabazitaxelum; TXD 258; XRP-6258; Jevtana Kit; TXD258; Cabazitaxel Injection; XRP 6258; kabazitaxel; NSC-761432; TXD-258; 51F690397J

GHS hazard classification

Reported hazard statements	H302 (85.7%), H311 (42.9%), H315 (85.7%), H317 (14.3%), H318 (14.3%), H335 (14.3%), H341 (85.7%), H360 (57.1%)

H302 (85.7%): Harmful if swallowed [Warning Acute toxicity, oral]

H311 (42.9%): Toxic in contact with skin [Danger Acute toxicity, dermal]

What the public record says

Cabazitaxel · CAS 183133-96-2 · C45H57NO14. UNII 51F690397J. Melting Point: 170.

Physical description and handling notes

Source: PubChem / Wikidata; the batch COA governs where values differ.